Introduction
============

Primary malignant melanoma of the esophagus (PMME) accounts for only 0.1 to 0.3% of all esophageal neoplasms ([@b1-mco-0-0-1572]--[@b3-mco-0-0-1572]), and the prognosis is extremely poor because of early hematogenous and lymphatic metastases. Standard treatment strategies and clear guidelines have not been established for PMME, much less for recurrent disease. There have been major recent advances in the management of metastatic melanoma, including immune checkpoint inhibitors, such as anti-programmed death-1 (anti-PD-1) and anti-CTLA-4 antibodies. In particular, targeting the PD-1 pathway in patients with metastatic melanoma has demonstrated a substantial clinical benefit ([@b4-mco-0-0-1572],[@b5-mco-0-0-1572]). However, there are currently no reports on the use of the anti-PD-1 antibody, nivolumab, followed by radiotherapy in patients with recurrent PMME. Here, we report a case of PMME that recurred in the lymph node (LN) around the celiac axis after thoracoscopic esophagectomy, which was treated with multidisciplinary therapy with dacarbazine, monoclonal antibodies directed against negative regulators such as PD-1, hypofractionated radiotherapy and laparoscopic lymphadenectomy.

Case report
===========

A 60-year-old Japanese man who presented with a chief complaint of dysphagia to solid foods was diagnosed with PMME in the lower esophagus. Because the patient had a prior history of right upper lobectomy for lung cancer, he underwent mediastinoscope-assisted subtotal esophagectomy with two-field LN dissection and gastric tube reconstruction via the mediastinal route. Evaluation of the resected specimen demonstrated that the tumor invaded the muscularis propria (pT2), and two nodal involvements were detected in the LNs along the left gastric artery (pN1). The UICC pathological staging for his PMME was IIA, T2, pN1, pM0. The resected specimen showed an elevated polypoid tumor 85×55 mm in size ([Fig. 1](#f1-mco-0-0-1572){ref-type="fig"}). Histopathologically, tumor cells consisted of malignant large tumor cells with abundant eosinophilic cytoplasm, and contained few melanin granules on hematoxylin and eosin (H&E) staining ([Fig. 2A](#f2-mco-0-0-1572){ref-type="fig"}). Subsequent immunohistology revealed that the tumor cells were positive for melan-A ([Fig. 2B](#f2-mco-0-0-1572){ref-type="fig"}), HMB-45 ([Fig. 2C](#f2-mco-0-0-1572){ref-type="fig"}), and S-100 ([Fig. 2D](#f2-mco-0-0-1572){ref-type="fig"}) and negative for cytokeratin markers, AE1/AE3 ([Fig. 2E](#f2-mco-0-0-1572){ref-type="fig"}), resulting in a diagnosis of PMME. Further analysis revealed a membranous staining pattern for programmed death ligand 1(PD-L1) ([Fig. 2F](#f2-mco-0-0-1572){ref-type="fig"}). The percentage of PD-L1 positive tumor cells within resected specimen was \~10% (anti-PD-L1 antibody; clone 28-8; ab205921; Abcam). No BRAF mutations were detected by direct sequencing analysis. Paclitaxel and S-1, an oral dihydropyrimidine-dehydrogenase-inhibitory fluoropyrimidine, were administered for 2 months as adjuvant therapy based on the results of a histoculture drug response assay (HDRA), which is a clinically practical *in vitro* drug-response assay for identifying optimal anticancer agents. Eight months after surgery, computed tomography (CT) revealed a 19-mm-diameter, oval-shaped mass in the LN around the celiac axis ([Fig. 3A](#f3-mco-0-0-1572){ref-type="fig"}), and ^18^F-fluorodeoxyglucose positron-emission tomography/CT (FDG-PET/CT) showed intense FDG uptake in the lesion ([Fig. 3B](#f3-mco-0-0-1572){ref-type="fig"}). No abnormal uptake was found at any other site of the body. Thus, based on imaging study findings, we diagnosed recurrence of disease in the LN around the celiac axis. The level of 5-S-CD was 12.6 nmol/l (reference value, 1.5--8 nmol/l) at the time of diagnosis of recurrent disease. Although there was only one site of recurrence, we first initiated nonoperative management because of a high rate of relapse. The patient received the first treatment session with dacarbazine (1,000 mg/m^2^, day 1) and interferon β (300 units/day, days 1--10); no substantial adverse effects were observed. CT performed after 4 courses after chemotherapy revealed progressive disease (PD) of the metastatic LN lesion according to response evaluation criteria in solid tumors (RECIST) ([Fig. 3C](#f3-mco-0-0-1572){ref-type="fig"}). Second, nivolumab, an anti-PD-1 antibody, was administered at a dose of 2 mg/kg every 3 weeks. After 8 treatment courses, CT revealed a partial response (PR) of the LN lesion ([Fig. 3D](#f3-mco-0-0-1572){ref-type="fig"}); however, after 4 more treatment courses, CT revealed PD of the LN lesion. During the first courses of nivolumab treatment, hyperthyroidism was observed, and predonizoron and potassium iodide were used to treat hyperthyroidism. Third, hypofractionated radiotherapy (RT) (4,000 cGy divided in 8 fractions) was targeted at the metastatic LN and resulted in a PR ([Fig. 3E and F](#f3-mco-0-0-1572){ref-type="fig"}); no substantial adverse effects were observed. Fourth, ipilimumab, an anti-CTLA-4 antibody, was given at a dose of 3 mg/kg. After initial administration of ipilimumab, grade 3 peripheral neuropathy \[defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0\] was recognized; thereafter, ipilimumab was not administered. Eighteen months after treatment for the metastatic LN, the LN decreased in size, and there were no other signs of metastasis to other organs. The patient then underwent laparoscopic celiac axis lymphadenectomy, and had no post-operative complications. Pathologic examination of the surgical specimens identified no viable melanoma cells ([Fig. 4A and B](#f4-mco-0-0-1572){ref-type="fig"}). Eight months after surgery, he is free from evidence of local and distant disease recurrence ([Fig. 4C](#f4-mco-0-0-1572){ref-type="fig"}). shows the clinical course and changes in the tumor marker 5-S-CD and in tumor size is shown in [Fig. 5](#f5-mco-0-0-1572){ref-type="fig"}. Written informed consent was obtained from the patient.

Discussion
==========

Metastatic melanoma is particularly difficult to cure because it shows resistance to therapies. An abdominal LN metastasis was detected 8 months after surgery, although the present case received adjuvant therapy for the prevention of cancer recurrence. Despite recent advances in melanoma treatment, interferon alpha is the only therapy currently licensed for the adjuvant treatment of melanoma, with documented success in improving recurrence-free survival and, to a lesser extent, overall survival (OS) ([@b6-mco-0-0-1572]). Therefore, adjuvant treatment based on the results of HDRA, which was developed as an *in vitro* drug-response assay for choosing anticancer agents ([@b7-mco-0-0-1572]), was given. The tumor inhibition rates of chemotherapy agents evaluated by the HDRA were found to be predictive of the response of various types of cancer to chemotherapy ([@b8-mco-0-0-1572]--[@b10-mco-0-0-1572]). Conventionally, a cytotoxic agent such as dacarbazine has been used for metastatic malignant melanoma. However, it is hard to say that dacarbazine has a high response rate. Inhibition of the PD-1 pathway by nivolumab improves OS compared with dacarbazine in advanced melanoma ([@b5-mco-0-0-1572]). Primary anorectal ([@b11-mco-0-0-1572]) and lung ([@b12-mco-0-0-1572]) malignant melanomas successfully treated with nivolumab were reported; however, to the best of our knowledge, this is the first case report regarding the administration of anti-PD-1 antibody followed by definitive hypofractionated RT for recurrent PMME. We administered dacarbazine as first-line therapy; however, we considered that dacarbazine therapy was not effective, and we started nivolumab as a second-line therapy. Nivolumab markedly reduced the tumor size. In this case, PD-L1 expression in tumor cells supported a response to nivolumab. Although malignant melanoma is generally considered to be radioresistant, hypofractionated RT led to a favorable outcome. Preclinical evidence suggests that PD-1 blockade may interact with RT to improve local tumor control in melanoma ([@b13-mco-0-0-1572]) and survival in glioma ([@b14-mco-0-0-1572]) in a variety of radiation dose and fractionation schema in breast cancer ([@b15-mco-0-0-1572]). Furthermore, Park *et al* reported that PD-1 blockade or deficiency can synergize with local radiotherapy to induce tumor-specific CD8-positive T-cell immunity ([@b16-mco-0-0-1572]). Only 3 clinical studies reported to date have focused on the relationship between anti-PD-1 antibody and RT. A retrospective cohort study reported that control of distant brain metastases and OS may be improved with anti-PD-1 antibody therapy and stereotactic RT compared with RT and/or surgery alone. Control of distant brain metastases and OS were not affected by the timing of anti-PD-1 antibody administration before, during or after stereotactic RT ([@b17-mco-0-0-1572]). A case series reported that neoadjuvant treatment for stage III/IV melanoma with anti-PD-1 antibody and hypofractionated RT had substantial clinical benefit without significant toxicity ([@b18-mco-0-0-1572]). A case report showed an abscopal effect, a rare phenomenon of tumor regression at a site distant from the primary site of radiotherapy ([@b19-mco-0-0-1572]), when radiotherapy was added to ongoing anti-CTLA-4 antibody therapy in a patient with melanoma ([@b20-mco-0-0-1572]). Prospective clinical studies of RT and anti-PD-1 antibody therapy in patients with melanoma and other malignancies are warranted. Anti-CTLA4 antibody therapy was additionally performed, although anti-PD-1 antibody therapy and RT have resulted in a PR. PMME is an extremely difficult malignancy because of early hematogenous and lymphatic metastases. Therefore, we did not intend to perform lymphadenectomy at first, and performed anti-CTLA4 antibody therapy to obtain complete response. However, severe peripheral neuropathy was recognized at the initial dose, and we determined to perform lymphadenectomy. The limitation of this case study is that we have not been able to show if anti-PD1 antibody was effective against PMME. Total remission was achieved rather after radiotherapy, however, we think that not only radiotherapy but also multidisciplinary therapy including anti-PD-1 antibody therapy were effective for PMME in this case because malignant melanoma is generally considered to be radioresistant, and there are some reports about synergic effect of RT and anti-PD-1 antibody ([@b13-mco-0-0-1572]--[@b18-mco-0-0-1572]).

In conclusion, we report the first case of recurrent PMME to be treated with combinations of chemotherapy, immunotherapy, RT and laparoscopic lymphadenectomy. This finding indicates that the combination of cytotoxic and molecular-targeted chemotherapy and RT may be suitable for select patients with metastatic PMME. Additional studies are needed to establish the usefulness of anti-PD-1antibody therapy for metastatic PMME.
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![Macroscopic view of the excised specimen shows an elevated polypoid tumor 85 × 55 mm in size.](mco-08-04-0528-g00){#f1-mco-0-0-1572}

![Histopathological findings. (A) Tumor cells stained with hematoxylin and eosin. (B) Immunohistochemical staining of tumor cells was positive for melan-A, (C) HMB-45, and (D) S-100 and negative for cytokeratin markers, (E) AE1/AE3 \[(A-E) original magnification, ×400. Scale bar, 200 µm\]. (F) Immunohistochemical membranous positive staining of PD-L1 in tumor cells (original magnification, ×100; scale bar, 500 µm.](mco-08-04-0528-g01){#f2-mco-0-0-1572}

![Computed tomography (CT) and ^18^F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET/CT). (A) Pre-treatment CT showing the metastatic lymph node (LN) around the celiac axis. (B) Pre-treatment FDG-PET/CT showing abnormal uptake of FDG in the metastatic LN (SUV~max~, 26.8). (C) CT showing the bigger metastatic LN after 4 courses of chemotherapy with dacarbazine and interferon β. (D) CT showing the smaller metastatic LN after 12 courses of nivolumab therapy. (E) CT showing the smaller metastatic LN after radiotherapy. (F) FDG-PET/CT showing no uptake of FDG in the LN after radiotherapy.](mco-08-04-0528-g02){#f3-mco-0-0-1572}

![Pathological findings of the surgical supecimen and CT image after celiac axis lymphadenectomy. (A) Macroscopic view of the resected lymph nodes. (B) Resected lymph nodes stained with hematoxylin and eosin. Necrosis and hyalinosis were observed in resected lymph nodes \[(B) original magnification, ×100. Scale bar, 500 µm.\]. (C) CT showing the no LN recurrence after lymphadenectomy.](mco-08-04-0528-g03){#f4-mco-0-0-1572}

![Clinical course and changes in the tumor marker 5-S-CD and tumor size. PTX, paclitaxel; DTIC, dacarbazine; INF β, interferon β.](mco-08-04-0528-g04){#f5-mco-0-0-1572}
